



**HAL**  
open science

## Mesenchymal stromal cells for systemic sclerosis treatment

Dominique Farge, Séverine Loisel, Pauline Lansiaux, Karin Tarte

► **To cite this version:**

Dominique Farge, Séverine Loisel, Pauline Lansiaux, Karin Tarte. Mesenchymal stromal cells for systemic sclerosis treatment. *Autoimmunity Reviews*, 2021, 20 (3), pp.102755. 10.1016/j.autrev.2021.102755 . hal-03163978

**HAL Id: hal-03163978**

**<https://hal.science/hal-03163978v1>**

Submitted on 19 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Mesenchymal stromal cells for Systemic sclerosis treatment

Dominique Farge<sup>1,2,3</sup> MD, PhD, Séverine Loisel<sup>4</sup>, PhD, Pauline Lansiaux<sup>1,2</sup> PhD, Karin Tarte<sup>5</sup>, PharmD, PhD

- 1 Unité de Médecine Interne : Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France, AP-HP, Hôpital St-Louis, F-75010 Paris, France
- 2 Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, EA3518, F-75010 Paris, France
- 3 Department of Medicine, McGill University, H3A 1A1, Montreal, Canada
- 4 SITI, CHU Rennes, Etablissement Français du Sang Bretagne, F-35000 Rennes, France
- 5 UMR 1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, F-35000, Rennes, France

### Author emails:

Dominique Farge: dominique.farge-bancel@aphp.fr

Séverine Loisel: severine.loisel@univ-rennes1.fr

Pauline Lansiaux: pauline.lansiaux@aphp.fr

Karin Tarte: karin.tarte@univ-rennes1.fr

### Corresponding author:

Pr Dominique FARGE,

Unité de Médecine Interne : Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France

Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, EA3518, F-75010 Paris, France

Department of Medicine, McGill University, H3A 1A1, Montreal, Canada

dominique.farge-bancel@aphp.fr

## ABSTRACT

Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterized by vasculopathy, dysregulation of innate and adaptive immune responses, and progressive fibrosis. SSc remains an orphan disease, with high morbidity and mortality in SSc patients. The mesenchymal stromal cells (MSC) demonstrate *in vitro and in vivo* pro-angiogenic, immuno-suppressive, and anti-fibrotic properties and appear as a promising stem cell therapy type, that may target the key pathological features of SSc disease.

This review aims to summarize acquired knowledge in the field of :1) MSC definition and *in vitro* and *in vivo* functional properties, which vary according to the donor type (allogeneic or autologous), the tissue sources (bone marrow, adipose tissue or umbilical cord) or inflammatory micro-environment in the recipient; 2) preclinical studies in various SSc animal models , which showed reduction in skin and lung fibrosis after MSC infusion; 3) first clinical trials in human, with safety and early efficacy results reported in SSc patients or currently tested in several ongoing clinical trials.

,

### Keywords:

systemic sclerosis, mesenchymal stromal cells, immune modulation, angiogenesis, fibrosis, clinical trials

## INTRODUCTION

Systemic sclerosis (SSc) is a rare chronic autoimmune disease with a prevalence of 38-341 cases per million adults. It is characterized by a pathogenic triad of 1) early endothelial damage and small vessel vasculopathy, 2) dysregulation of innate and adaptive immune responses, and 3) progressive fibrosis primarily affecting the skin, gastrointestinal tract, lungs, heart, and kidneys, resulting in multi-organ dysfunction [1,2]. Health-related quality of life (HRQoL) is considerably impaired for these patients [3,4]. Disease presentation is heterogeneous, with high morbidity and a standardized mortality ratio of 3.5, compared to the general population [5]. The leading causes of death are cardiac [6] and pulmonary [7,8] involvement, and the 8-10-year mortality rate is over 20-30% [5,6,8]. In cases of rapid and diffuse progression, which accounts for 10 to 20% of the SSc population, the 3-5-year survival rate is estimated at 50-70% [9,10], depending on the type and extent of organ involvement.

SSc remains an orphan disease with high unmet therapeutic needs. The recommended treatments are mostly symptomatic for Raynaud's phenomenon and gastro-esophageal reflux [11]. Standard immunosuppressive drugs, including cyclophosphamide and mycophenolate mofetil, for early severe or rapidly progressive forms, have modest effects without improving survival [12]. Several immunotherapies that specifically target cytokine signaling (eg.: Interleukin (IL)-6), B cells (with anti-CD20 therapy), T cells (with inhibition of T-cell co-stimulation), or other specific fibrosis signaling pathways, such as anti-transforming growth factor (TGF)- $\beta$  agents are under investigation, but have yet to be approved as disease-modifying therapies in SSc.

In this context, stem cell therapies are emerging as a new therapeutic option for SSc. Autologous hematopoietic stem cell transplant (AH SCT) was the first intervention to have disease modifying properties [13–15], including regression of skin [16] and lung [14,17] fibrosis, allowing improvement in both overall survival (OS) and event-free survival (EFS) up to 5-7 years after transplant. However, the procedure is contraindicated in cases with advanced visceral involvement [18,19], and its use is restricted to the most severely affected patients, which represent 20 to 30 % of the SSc patient population. Mesenchymal stromal cells (MSC), first identified in the bone marrow (BM-MSC) 25 years ago by Friedenstein [20], have been extensively characterized [21–24]. MSC can be easily harvested from various other sources including adipose tissue (AD-MSC), and umbilical cord or Wharton jelly (UC-MSC). These multipotent progenitor cells modulate both innate [25] and adaptive [26] immune systems, and have pro-angiogenic and anti-fibrotic properties, all providing a strong rationale for their use to target the SSc pathogenic triad [27,28].

## **1. PATHOPHYSIOLOGY OF SYSTEMIC SCLEROSIS**

Although the exact cause of SSc remains undetermined, numerous studies show that a complex interplay between genetic susceptibility and environmental factors (such as exposure to silica dust and organic or occupational solvents) triggers disease onset with consequent endothelial damage and microvascular injury, inflammation, and autoimmune activation [1,2]. These factors contribute to fibroblast activation, enhanced collagen and extracellular matrix protein production, with consequent fibrosis, and disease progression.

### **1.1 Genetic susceptibility**

SSc is not a monogenic disease [29]. Multiple gene polymorphisms have been associated with a predisposition to developing SSc. While the SSc concordance rate between monozygotic twins is low (4.2%) compared to other autoimmune diseases [30], the relative risk of SSc is ~1% among relatives of SSc patients. These individuals also have a higher frequency of other autoimmune disorders [31]. Candidate gene studies and genome-wide associated studies (GWAS) [32], immunochip data, and whole exome sequencing (WES) have identified many SSc-associated polymorphisms (reviewed in [29,33–35]). Genetic susceptibilities are insufficient to explain disease entirely, underlining the importance of environmental and epigenetic dysregulation, as recently reviewed [29,33,35,36]. Evidence supporting the latter include: 1) abnormal DNA methylation of the promoter region of genes encoding for costimulatory molecules, such as CD70 on activated lymphocytes or CD40LG on activated T cells, FOXP3 on peripheral blood CD4+ cells [29,33,35,36], Friend Leukemia-Integration (FLI-1) in keratinocytes, endothelial cells, and lung fibroblasts, and Bone morphogenetic protein receptor type II (BMPRII) and nitric oxide synthase 3 (NOS3) in endothelial cells; 2) abnormal histone acetylation resulting in Krüppel-Like Factor 5 (KLF5) and Friend leukemia integration 1 transcription factor (FLI1) epigenetic repression and increasing connective tissue growth factor (CTGF) in fibroblasts from SSc patients, and abnormal histone methylation associated with abnormalities in Transforming Growth Factor- $\beta$  (TGF- $\beta$ )-SMAD signaling pathways; 3) changes in non-coding RNA expression in immune cells, fibroblasts, and in serum levels of micro RNAs that correlate with disease phenotypes and activity.

### **1.2 Vasculopathy**

Vascular injury and endothelial cell damage occur early in SSc [37], with infiltration and accumulation of immune cells in affected tissues [1,2,38,39]. The primary trigger is thought to increase reactive oxygen species (ROS) and cause mild oxidative stress [2,37]. Endothelial cells undergo vacuolization and apoptosis, resulting in break-down of the endothelial lining [39]. The interaction between leukocytes

and endothelial cells increases endothelial cell permeability, with upregulation of the expression of cell adhesion molecules, and secretion of chemokines and mediators of trans-endothelial leukocyte migration by the activated endothelial cells [38]. Perivascular infiltration and proliferation of monocytes, macrophages, mast cells, T-lymphocytes [40], and autoantibody-producing cells all contribute to cytokine release [41]. Autoantibodies against the native platelet-derived growth factor (PDGF) receptor in scleroderma patients [42], were shown to trigger tyrosine phosphorylation and ROS accumulation and to stimulate type I collagen expression as well as conversion of normal human primary fibroblast into myofibroblast. Angiogenesis is also altered in SSc, with inadequate proliferation and differentiation of endothelial cells in response to endothelial injury [37,38]. Endothelial damage, dysfunctional angiogenesis, and sustained inflammation lead to progressive structural alterations and loss of small blood vessels, particularly arterioles [37]. Vascular smooth-muscle cells and pericytes proliferate actively in early SSc, with progressive thickening of the perivascular wall. Pericytes infiltrate the perivascular space and can transdifferentiate into vascular smooth-muscle cells, fibroblasts, or myofibroblasts [37].

### **1.3 Activation of the innate and the adaptive immune responses**

Activation of the innate immune response has been shown for long in SSc, with the presence of monocytes, macrophages [43], mast cells, and dendritic cells (DC) in skin [44–47] and lung [48] biopsies, even before the detection of vasculopathy and altered endothelial cells. Activation of the adaptive immune response [49] is present at early stages, with predominant T lymphocyte infiltration [40,50,51] in the skin and lung, and auto-antibody production [52,53], which all may precede disease symptoms. Immune system activation contributes to large amount of cytokine release [41] and further promote inflammation and fibrosis [54]. More recently transcriptome analysis within the peripheral blood [55] and skin [56–58] samples have shown variables degrees of upregulation of the immune response signatures, according to disease and activity stages [59].

In the early inflammatory phase of SSc, Toll-like receptors (TLR) signaling in innate immune cells, which can be triggered by pathogens, cellular damage, or stress, is an important driver of inflammation [60,61]. TLR activation in macrophages and dendritic cells triggers production of interleukins (IL)-1, IL-6 and tumor necrosis factor (TNF)- $\alpha$  [62], and results in the release of inflammatory cytokine release, including type I interferons (IFNs). IFN- $\alpha$  induces inflammation and activation of other innate immune cells, such as classical DC (cDC), which in turn lead to increased production of cytokines (IL-6, TNF- $\alpha$ ), chemokines (CXCL10, CCL4), and cell adhesion molecules (P selectin, glycoprotein ligand (PSGL-1)). DC promote inflammation, myofibroblast transformation, and extracellular matrix (ECM) deposition in

affected tissue from SSc patients [47,63]. Upregulated CXCL4 production by plasmacytoid DC (pDC) can modulate monocyte differentiation into monocyte-derived inflammatory DC with increased TLR-mediated cytokine production, superior T-cell stimulation, and a profibrotic phenotype [47,63]. TLR-4 expression is elevated in SSc skin and lung biopsies, with robust TLR4 staining in fibroblast and vascular cells of affected tissues, and correlates with disease progression [64]. A high level of skin TLR-9 expression and downstream pathway activation contributes to endogenous TGF $\beta$  production and fibrosis. pDC produce high levels of IFN $\alpha$  [65], CXCL4 and TLR-8, and activated cDC are the most efficient inducers of T cell activation.

T cells play a critical role in the pathogenesis of SSc and can also influence autoantibody synthesis [50]. CD4<sup>+</sup> and CD8<sup>+</sup> T-cells have been identified in skin [66–68] and lung [69,70] of SSc patients and the two subpopulations may contribute to different disease stages [68]. CD4<sup>+</sup> T cells could differentiate into various functionally and phenotypically different subtypes, including Th1, Th2, Th17, Treg (T regulatory cells), and Tfh (T-follicular helper), depending on the cytokine context [41,71–73]. Although the exact role of IL-17 in fibrinogenesis remains controversial (ie.: trans-differentiation of human fibroblast into myofibroblast, collagen synthesis), Th17 cells and IL-17 production were found to be elevated in the peripheral blood, skin, and lungs from SSc patients, and to participate in and exacerbate early inflammatory responses [74–76]. Restoration of the Th1/Th2/Th17/Treg cytokine balance is an important goal of therapy.

At early stages of SSc, macrophages and Th1 cells are the predominant inflammatory cell types to induce inflammation, which is associated with IFN-type I upregulation. Tissue resident macrophages are activated by Interferon (M1, classically activated) and IL-4 (M2, alternatively activated), and become fibrotic with exposure to type 2 cytokines, such as IL-6 [62] and IL-13 [77,78]. Reduced numbers [79,80] and altered suppressive functions [81–84] of Treg cells also contribute to immune activation [78,84]. B cell activation is associated with phenotypic and functional changes and contributes to autoantibody production [85]. Cell surface expression of CD19 is upregulated in peripheral blood B cells [86], which regulates B cell receptor-induced signaling and antibody production. CD95, CD80 and CD86 are also upregulated in memory B cells [86–88], as well as B cell activating factor (BAFF) [89], which also contribute to the regulation of B cell-induced immunoglobulin production and secretion [52]. In addition, B cells can also act as antigen-presenting cells to T cells and induce dendritic cell maturation, promoting Th2 profibrotic responses [90].

#### **1.4 Fibrosis**

Early vascular inflammation is eventually replaced by a fibrotic stage. CD4<sup>+</sup> and CD8<sup>+</sup> T cells undergo expansion in response to cytokine release [51,66,67], which in turn activates fibroblast and stimulates collagen production via direct or indirect mechanisms. Fibroblasts can be activated by the two major pro-fibrotic cytokines, transforming growth factor- $\beta$  (TGF- $\beta$ ) [91] and connective tissue growth factor (CTGF), as well as through interactions with the other immune mediators and growth factors. Fibroblast activation results in excessive deposition of collagen and remodeling of other ECM components associated with progressive diffuse fibrosis, loss of small vessels, hypoxia, and consequent alterations in skin and internal organ architecture and function [92,93]. Plasma levels of Th2/Tc2 cytokines (IL-4 and IL-13) are elevated in SSc patients compared with healthy controls [41]. Fibroblasts can be recruited by chemotaxis to sources of TGF- $\beta$ , IL-4, TNF- $\alpha$ , PDGF and ET-1, and will proliferate in response to IL-1, IL-4, IL-6, IL-17, ET-1, PDGF, or TGF- $\beta$ . These profibrotic cytokines, as well as TGF- $\beta$ , stimulate differentiation and activation of myofibroblasts, with increased ECM production leading to fibrosis. Disruptions in the ECM vary with disease progression; changes in different collagens, proteoglycans, and fibrillins [94] occur typically earlier in the disease, with type I collagen accumulating in later disease stages.

## 2. DEFINITION AND CHARACTERISATION OF MESENCHYMAL STROMAL CELLS (MSC)

*In vitro* expanded MSC are defined a minima since 2006 by the International Society for Cellular Therapy (ISCT) MSc committee, as : 1) a plastic-adherent polyclonal population with fibroblast-like morphology, 2) expressing CD73, CD90 and CD105 (in > 95% MSC), 3) in the absence of hematopoietic and endothelial markers, and 4) able to differentiate *in vitro* into osteoblasts, adipocytes, and chondroblasts [21]. Importantly, MSC are not equivalent to mesenchymal stem cells, referring to cells with validated *in vitro* and *in vivo* self-renewal and multi-lineage differentiation potential at the clonal level [95]. Some MSC effects are mediated by direct cell-cell contact, but most of their action is exerted through secretion of soluble factors, which are not constitutively expressed by MSC, but are induced by several proinflammatory cytokines in the local milieu.

MSC secrete growth factors, cytokines, and hormones [96–99], which are central to MSC paracrine activities, all contributing to tissue regeneration in various diseases, including for SSc patients [100,101] [96–99]. Together with this short-lasting bystander trophic activity, the clinical potential of MSC has been proposed to depend on their wide immunosuppressive and anti-inflammatory potential, suggesting that immunomodulation facilitates host tissue regeneration [102,103]. Numerous parameters have been proposed to modulate MSC functional properties, including the tissue source and the production process, and also the inflammatory environment, since MSC immune properties are



essentially not constitutive, but licensed (also called MSC priming) by inflammatory stimuli (e.g. IFN- $\gamma$   $\pm$  TNF- $\alpha$ , IL-1 $\alpha$  or IL-1 $\beta$ ) [104–106]. Therefore, the expression of surface markers and MSC functional features may change according to culture conditions, cryopreservation, and inflammatory status [104], and these properties are critical for clinical application and the interpretation of MSC studies [107,108]. Importantly, MSC priming also increases the expression of major histocompatibility complex (MHC) class I and induces MHC class II molecules and MSC are recognized and killed by activated immune cells. The early concept of MSC as being immune-privileged is thus more accurately described as immune-evasive [23,109].

## **2.1 Different sources of MSC**

MSC, originally identified in the bone marrow (BM) stem cell niche [20,24], were subsequently isolated from adipose tissue, dental pulp, synovial membranes, placenta, umbilical cord, and Wharton's jelly [110,111]. The most frequent sources of MSC for therapeutic use have been bone marrow (BM-MS), adipose tissue (AD-MS) [112], and fetal tissues [111] [umbilical cord (UC-MS) tissue or blood, Wharton's jelly, and placenta]. While MSC from these sources share many biological features, they differ in terms of their proliferation potential, multilineage capacities, overall transcriptional profile, and functionality [107,113–117].

BM-MS were first considered as the main source of MSC used in clinical trials, although their capacity to proliferate and differentiate changes significantly over time, decreasing with age, and varies extensively according to donor sources [107,118]. It requires a painful invasive procedure to obtain BM sample in the donor and there is a risk of viral exposure. Adipose-derived MSC (AD-MS) isolated from the stromal vascular fraction (SVF) of subcutaneous adipose tissue can yield up to a 500-fold higher number of MSC compared to bone marrow [119]. Recently, the first transcriptomic, phenotypic and functional analyses on paired BM-MS and AD-MS samples from the same healthy donor, showed stronger inhibition of immune responses by AD-MS and lower immunogenicity, providing a new rationale to support the use of adipose tissue as a source of MSC for the treatment of immune-mediated diseases [120]. UC-MS as well as MSC from other perinatal tissues (ie.: amniotic membrane, chorionic membrane, placental decidua and Wharton Jelly) are an interesting alternative cell therapy product, as they can be isolated and cryopreserved in a non-traumatic and ethical way (reviewed in [121]). Of interest, UC-MS may be less immunogenic due to a lack of MHC class II upregulation in response to IFN- $\gamma$  [122–124]. In addition, they display a unique gene expression profile, including genes involved in immunomodulation, angiogenesis, and wound healing, compared to BM-MS as evaluated by single cell RNA seq technology [125].

These three types of MSC all secrete angiogenic, antiapoptotic, and anti-inflammatory cytokines with different cytokine profiles according to tissue source and donor type [126]. Which tissue is best for a particular therapeutic application is a question that is currently under evaluation in SSc patients. Indeed, a comprehensive comparison of UC-MSC versus AD-MSC and BM-MSC is still lacking.

In addition to MSC tissue source, the culture conditions, including culture medium and scale of expansion, and the use of cryopreservation were shown to affect MSC functions [126]. In particular, both the onset of replicative senescence associated with huge *in vitro* expansion and the use of cryopreservation were shown to impact the immunosuppressive functions and the *in vivo* persistence of clinical-grade MSC, which can be partly restored by *in vitro* licensing by inflammatory stimuli [127–131]. Each of these numerous sources of heterogeneity during the MSC production process [107] and their release for therapeutic use has to be considered when designing clinical trials [126].

## **2.2 MSC immunomodulatory and immunosuppressive properties**

MSC exert their immunomodulatory and immunosuppressive effects on both innate and adaptive immune cells through a wide panel of mechanisms [100,101].

*In vitro* data showed that MSC modulate the immunological activity of the different cell populations engaged in the pathogenesis of systemic sclerosis (Figure 1), which led us and others to evaluate MSC potential therapeutic values in SSc patients [28]. First, MSC inhibit DC differentiation, maturation, cytokine expression and capacity to present antigens to T lymphocytes [132,133]. They influence antigen presentation by DC via downregulation of DC cell surface expression of MHC class II, CD11c, and CD83, which modulate their anti-inflammatory action [134]. MSC directly modulate T cell activation, proliferation, differentiation, and effector function. MSC inhibit the proliferation of both naïve and memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells through arrest in the G0/G1 phase of the cell cycle [135], and abrogate T cell activation [116,136–138]. Interestingly, MSC also influence the differentiation of naïve CD4<sup>+</sup> T helper cells by promoting anti-inflammatory immune responses and affect the balance of T cell polarization [139]. Thereby, in an inflammatory setting, MSC appear to increase the number and activity of Treg cells and IL-10 expression, while suppressing Th1, Th2, and Th17 cells [140,141]. MSC can reduce the release of pro-inflammatory cytokines from different T cell populations, including interferon IFN- $\gamma$ , TNF, IL-6, and IL-7, and increase anti-inflammatory cytokines, such as IL-4 and IL-10 [139,142]. MSC can also inhibit IL-2-induced proliferation of resting NK cells and partially inhibit the proliferation of activated NK cells and thereby NK mediated cytotoxicity [143]. Besides, MSC also inhibit B cell proliferation, antibody production, and chemotaxis under inflammatory conditions [116,144], and favor

Breg expansion. Inhibition of B cell proliferation appears to be indirect, as it requires the presence of CD4<sup>+</sup> and CD8<sup>+</sup> T cell lymphocytes [145].

*MSC effects are mediated in part by direct cell-cell contact.* In particular CD106/VCAM-1 and CD54/ICAM-1, that are both upregulated on MSC by TNF $\alpha$ , play a critical role in the immunosuppressive capacities of MSC by favoring adhesion to T cells [146]. In addition, CD54 is specifically upregulated and enriched at the contact area between inflammatory macrophages and MSC, thus increasing their immunosuppressive capacities [147]. MSC were also shown to directly promote apoptosis of activated T cells via the Fas/Fas ligand pathway [148] and to suppress T cell proliferation via engagement of the inhibitory molecule programmed death 1 (PD-1) by its ligands PD-L1 and PD-L2 [149]. PD-1/PD-L1 axis was also proposed as involved in the repression of Th17 differentiation program by MSC [150]. Interestingly, human MSC also express several ligands for activating NK cell receptors such as ULBP3, poliovirus receptor (PVR) and nectin 2 (also known as PVRL2). In agreement, they can be lysed by activated NK cells but not by freshly isolated NK cells [151–153]. Interestingly, treatment of MSC with IFN- $\gamma$  leads to the upregulation of MHC class I expression and the downregulation of ULBP3 expression [97,143,154], making them more resistant to NK cell cytotoxicity [153].

*Most MSC effects are paracrine and exerted through secretion of soluble factors.* Typically, the mechanism of action of MSC first involves the release of chemokines allowing attraction of activated T cells [98], that in turn produce proinflammatory cytokines responsible for the priming of MSC towards an immunosuppressive phenotype. In turn, MSC secrete growth factors, cytokines, enzymes and hormones (e.g., VEGF, PDGF, ANG-1, IL-11, PGE2, TSG-6, SDF-1, HGF, IGF-1, IDO) [96–99], which are central to MSC paracrine activities. Immunosuppressive soluble factors secreted by MSC *in vitro* include indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes transformation of tryptophane to kynurenine [143,155], which is involved in inhibition of B cell and T cell proliferation and in the polarization of monocytes into IL-10-secreting M2 macrophages [156]. Non-inflammatory resting MSC, that do not express IDO, induce expansion of IL-10-expressing Breg, instead of inhibiting B cell proliferation and differentiation, through poorly characterized soluble factors [144,157]. Apart from the central role of IDO/iNOS, other soluble factors have been proposed to contribute to the inhibition of T cell proliferation, including galectin-1 and 3 [158,159], or IL-10 [160]. Conversely, the capacity of MSC to induce Treg is mediated by TGF- $\beta$  [161] and soluble HLA-G5 [162], with IL-10, IL1R $\alpha$ , and PGE2 further impacting the Th17/Treg balance [163]. HLA-G5 and PGE2 have both been shown to be involved in the suppression of NK function [143,162]. Moreover, PGE2 abrogates the monocyte differentiation into DC, and contributes to the repolarization of macrophages into anti-inflammatory M2 macrophages

producing IL-10 [164,165]. Other immunosuppressive activities of MSC on myeloid cells are driven by soluble factors, such as CCL2 and CXCL12 that cooperate as a heterodimer to upregulate IL-10 in CCR2pos macrophages [166], tumor necrosis factor-stimulated gene 6 (TSG-6) that promotes the early inhibition of neutrophil and macrophage activity at sites of inflammation and inhibits CXCL8-dependent neutrophil transendothelial migration and chemotaxis [167–169], and IL6 that is responsible for the blockade of monocyte differentiation into DC [170]. Finally, HGF displays both anti-inflammatory and anti-fibrotic effects [171] and has been proposed to favor the development of myeloid-derived suppressor cells (MDSC) together with PGE2 [172,173].

*MSC also produce extracellular vesicles (EVs), including exosomes, microvesicles and apoptotic bodies, which are small (44-100 nm in diameter) membrane vesicles.* These exosomes have immunosuppressive and immunomodulatory activity, and have been found to favor Treg expansion [174,175], potentially mediated by an increased secretion of IL-10 and TGF- $\beta$ 1 by DC [176]. Human MSC-EVs were shown to polarize macrophages to a regulatory phenotype in a PGE2-dependent manner *in vitro* [177]. In addition, MSC-derived exosomes support the differentiation of suppressive M2 macrophages in a mouse model of breast cancer, via carrying high levels of TGF- $\beta$ , semaphorins, and complement factors, [178]. Exosomes from IFN- $\gamma$ -activated MSC were also shown to improve the clinical score in a mouse model of colitis, due to increased amounts of micro ribonucleic acid family miR-125a and miR-125b, which repress Th-17 differentiation by targeting stat3 [179]. MSC-derived EVs in various preclinical models, together with their immunosuppressive and regenerative activity, encourages their use in clinical setting, as cell-free products with highly scalable/quality-controllable production process and interesting safety profiles [180].

*Other mechanisms for MSC immunosuppressive actions were recently discovered using in vivo models.* Among these, MSC mitochondrial transfer increases the phagocytic capacity of lung macrophages, and thereby favors bacterial clearance in sepsis [181,182]. In addition, artificial mitochondrial transfer from MSC to T cells was shown to trigger transcriptomic, metabolic, and functional reprogramming and to favor Treg differentiation [183]. Efferocytosis, the process by which apoptotic cells are engulfed, has been associated with the capacity of MSC to upregulate PGE2 and IL-10 [184]. When MSC are infused intraperitoneally in mice with Graft versus Host Disease (GvHD), efferocytosis also accounts for their immunosuppressive activity, leading macrophage toward IDO expression. However, MSC improve GvHD only when infused intraperitoneally [99], and the efficacy of apoptotic MSC in this model was substantially lower than that of live MSC [185].

*MSC immunopotency assays.* In 2016, the MSC committee of the ISCT published guidelines addressing the characterization of MSC immune modulatory properties [23]. Since MSC deploy a panel of immunomodulatory and regenerative properties, largely dependent on their interaction with their microenvironment. Standard functional markers of MSC potency as well as release potency assays have been defined for conducting advanced clinical studies and their potential registration [23,186]. Standardized methods have been proposed to assess MSC functional properties [187]. The preferred analytic methods for matrix assays evaluating the immunosuppressive and immunomodulatory capacities of MSC [188,189] currently include: a) quantitative RNA analysis of selected gene products [190], b) flow cytometry analysis of functionally relevant surface markers, and c) protein-based assay of secretome. Recently, a combination of transcriptome and secretome analyzes has been proposed as predictive of T cell immunosuppressive properties [191] but additional quantitative assays are urgently required to capture the whole MSC immunosuppressive, anti-inflammatory, and regenerative potential that could synergistically improve SSc patient behavior. Similarly, standardized high-throughput multiparametric immunomonitoring tools have to be set up to characterize the patient immunological status and the various immune cell subsets before and after MSC treatment, to identify responders and thereby optimize clinical trials design.

### **2.3 MSC proangiogenic and antifibrotic properties: *in vitro* evidence**

The angiogenic potential of MSC was first demonstrated by their capacity to differentiate towards an endothelial cell lineage [192]. Adult human BM-MSC can be expanded *in vitro* and differentiated into cells with phenotypic and functional features of endothelial cells able to form capillary-like structures [193–195]. A broad complement of angiogenic factors has been identified in the BM-MSC secretome, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)-2, placental growth factor (PLGF), angiopoietin (Ang)-1, monocyte chemoattractant protein-1 (MCP-1), and IL-6 [196–199]. Human AD-MSC can also give rise to CD34<sup>+</sup> and CD13<sup>+</sup> populations, which can spontaneously differentiate into endothelial cells *in vitro* and participate in the formation of vascular structures in a Matrigel model [192]. AD-MSC secrete angiogenic and antiapoptotic factors, such as VEGF, hepatocyte growth factor (HGF) [200], leptin [201], basic fibroblast growth factor (bFGF), Ang-1, Ang-2, platelet derived growth factor (PDGF) [202–204], as well as mesenchymal stem cell-like protein (MSCP1) and stromal cell-derived factor-1 (SDF1), which are essential for vascular remodeling [205]. The combination of VEGF and shear stress can enhance endothelial differentiation of AD-MSC [206]. More recently the angiogenic/angiostatic signaling pathways by which AD-MSC support neo-vessel formation and stabilization were described, elucidating the functional interaction between AD-MSCs and endothelial

cells [207–211], and AD-MSC appear to be more effective in this regard than their counterparts from bone marrow. Placental MSC also secrete angiogenic factors such as IL-6 [212]. The secretion of angiogenic factors by MSCs can be upregulated according by different chemokines and local hypoxia [206,213]. In BM-MSC, TGF $\beta$  induces secretion of several growth factors, including VEGF, HGF, PDGF-BB, Ang-2, IL-6, and IL-8 [213].

The contribution of the MSC secretome to inhibiting or reversing fibrosis in the SSc pathologic microenvironment is not well understood. MSC-conditioned medium can inhibit proliferation of lung fibroblasts *in vitro* and improve regeneration of injured lung epithelium in an alveolar epithelial wound repair assay [214]. There is currently no consensus on which assays should be used to assess anti-fibrotic activity of MSC *in vitro*, which is crucial for the selection of MSC products to be used in the therapeutic setting, including for clinical trials.

### 3. MSC IN EXPERIMENTAL ANIMAL MODELS OF SYSTEMIC SCLEROSIS

MSC have been investigated in several animal models of SSc [92,215], although none of these encompass all the features of the disease [92]. Table 1 summarizes common animal models of SSc.

Subcutaneous injection of bleomycin, an antitumor antibiotic agent that arrests cells in the G2 phase, is used as a model of skin and lung fibrosis, with mononuclear cell infiltration, antinuclear antibody production, and dermis thickening at sites of injection and in alveolar walls. Reactive oxygen species (ROS) produced by bleomycin cleave DNA, and induce oxidative RNA degradation and lipid peroxidation. Cell damage induced by free-radicals, subsequent recruitment of immune cells, and release of pro-fibrotic mediators appear to underlie the fibrotic response. SMA-positive myofibroblasts observed in the skin gradually increase with dermal sclerosis. Using this model, BM-MSC from male bleomycin-resistant Balb/C mice transplanted into female C57BL/6 mice exposed to intratracheal bleomycin [216] were localized by *in situ* hybridization to areas of bleomycin-induced injury, consistent with MSC homing. MSC infused immediately after bleomycin exposure reduced the extent of bleomycin-induced inflammation and collagen deposition in the lung, but not when MSC infused 7 days after exposure to bleomycin. In rats, injection of BM- MSC 4 days after bleomycin exposure reduced neutrophil infiltration and collagen deposition, as well as nitric oxide metabolites and cytokines [217]. In this model, two weeks after rat BM- MSC injection [218], TGF $\beta$ 1, PDGF-A, PDGF-B, and IGF-I mRNA expression in lung tissue was decreased, as measured by real-time PCR.

The effect of a myelosuppressive regimen with busulfan prior to similar intratracheal bleomycin exposure 6 hours before injection of BM-MSC derived from GFP-positive C57BL/6 mice was examined in

C57BL/6 recipient mice [219]. Myelosuppressive conditioning significantly decreased 14-day survival following bleomycin exposure, but all MSC-treated animals survived, whether they were myelosuppressed or not. Injured lung cells cultured in vitro secreted factors that increased MSC proliferation and homing to the injured lung cells in a migration assay. Similarly, AD-MSc infusion 24 hours after intratracheal bleomycin exposure in C57BL/6 mice reduced lung and dermis fibrosis, and accelerated wound healing [220].

UC-MSc isolated from Wharton's jelly were infused 24 hours after intranasal bleomycin exposure in severe combined immunodeficiency (SCID) mice to minimize potential rejection of human cells [221]. UC-MSc were localized at sites of injury and fibrosis in lung two weeks after infusion and were no longer found in lung 28 days after infusion. MSc infusion reduced bleomycin-induced pneumonitis and lung fibrosis. Quantitative PCR identified a decreased expression of IL-10, TNF- $\alpha$ , TGF- $\beta$ , and IFN- $\gamma$  in lung with MSc treatment. In mice simultaneously receiving infusions of AD-MScs isolated from C57/BL6 GFP-positive mice ( $2 \times 10^6$  in 100  $\mu$ l), dermal thickness and hydroxyproline content were significantly reduced 4 weeks after transplant [222].

In the SSc hypochlorite (HOCl)-injected mouse model, daily subcutaneous injections of HOCl in BALB/c mice produce ROS, anti-DNA topoisomerase 1 antibodies, progressive collagen deposition, and early and continued skin and lung fibrosis that best reproduce human pathological findings [223]. In this model, a single infusion of allogeneic BM- MSc immediately after HOCl exposure in BALB/c mice ( $2.5 \times 10^5$ ,  $5 \times 10^5$ ,  $5 \times 10^6$  cells) significantly reduced skin and lung fibrosis [224]. The lowest dose ( $2.5 \times 10^5$ ) examined was the most effective, with sustained reduction of fibrosis, advanced oxidative protein products and total collagen content until 42 days. Markers of fibrosis and cytokine expression were lower in lung tissue after MSc infusion. Only fibrosis marker expression was significantly reduced in skin and only with the lowest dose. Serum levels of anti-scl-70 auto-antibodies were also lower in all mice that received MSc infusions. MSc treatment transiently improved skin thickness in HOCl-exposed mice, with a rate of disease progression similar to untreated mice after day 21 and no additional treatment benefit after this point. In mice that received a second MSc infusion on day 21, a significantly slower progression of skin thickening between day 21 and 42 was observed. In mice with established SSc, the effects of a late single MSc infusion were observed from 1 week after treatment onward, with significant reductions in skin and lung fibrosis. Both allogeneic and xenogeneic MSc were examined in the SSc (HOCl)-induced mouse model [225]. BALB/c mice exposed to HOCl were infused with syngeneic BALB/c MScs, allogeneic C57BL/6 MSc, or xenogeneic human MSc isolated from either bone marrow or adipose tissue. In each of these condition MSc were collected from 3 donors. All the sources of MSc appeared to have similar

therapeutic effects, including a decrease in skin thickness, collagen levels in skin and lung, and expression of collagen 1, collagen 3, and  $\alpha$ Sma [225,226].

Various labeling methods have been used to analyze MSC biodistribution and homing, but these techniques cannot confirm sustained cell viability, in either animals or humans [227–229]. While studies have identified mechanism by which MSCs can migrate to sites of injury and participate in tissue repair [230], studies in mice have reported that MSC are rapidly removed from circulation (~24 hours) after iv injection; the cells are first trapped in lung, then transmigrate beyond vascular spaces, where most MSC are rapidly phagocytosed by lung-resident tissue macrophages [164]. The adhesion molecules VLA-4/VCAM-1 influence interactions between MSCs and endothelial cells during transmigration in the lung. The fucosylation of CD44 to HCELL, a highly active E-selectin ligand on MSC, may also modulate MSC homing to bone marrow endothelium [231]. The term “medicinal signaling cells” (MSC) proposed by Caplan [24] reflect that *in vivo* MSC “release therapeutic agents *in situ* at site of injury, disease, or inflammation” due to their secretory properties.

#### **4. USE OF MSC IN SSC PATIENTS: CLINICAL STUDIES**

Although we and others initially reported that MSC obtained from SSc and healthy controls inhibit proliferation of mixed peripheral blood mononuclear cells and T cell proliferation at similar rates [232,233], when specifically co-cultured with PHA-conditioned T lymphocytes [232], disease-specific abnormalities in MSC from SSc patients later emerged [234,235].

##### **4.1 Abnormal MSC in SSc patients**

BM-MSc from SSc patients have increased TGF $\beta$ -R2 on their cell surface, and a higher sensitivity to TGF $\beta$ , resulting in excessive production of collagen 1, contributing to tissue fibrosis [236]. BM-MSc samples from SSc patients also have reduced clonogenicity (assessed in colony-forming unit fibroblast (CFU-F) assay) [234], and undergo early senescence (increased  $\beta$ -Gal activity), with a significantly decreased proliferation rate (lower ki67 gene expression, higher p21 transcript level) [237]. SSc BM-MSc also demonstrate a reduced capacity to differentiate into endothelial progenitor cells, osteoblasts, and adipocytes, as well as angiogenic dysfunction [235]. When co-cultured with CD4<sup>+</sup>CD25<sup>-</sup> lymphocytes, TGF- $\beta$  expression is significantly higher in MSc derived from SSc patients, compared to healthy controls. Cell surface expression of TGF $\beta$ -RII is also increased SSc MSc, resulting in a higher sensitivity to TGF- $\beta$  [237]. In the presence of TGF- $\beta$ , SSc MSc significantly increase collagen 1 $\alpha$  synthesis and Smad-3 phosphorylation, which contribute to tissue fibrosis [236]. A recent study confirmed that the proliferation rate, metabolic activity, and migration and invasion potential of AD-MSc was decreased in



SSc patients compared to normal controls [238]. These data support the use of MSC from umbilical cord or other allogeneic (instead of autologous) MSC sources for SSc treatment.

The SDF-1/CXCR4 axis is involved in MSC recruitment at sites of injury and in angiogenesis. Compared to healthy controls, SDF-1 is upregulated in MSC derived from SSc patients, although CXCR4 expression is comparable [239]. TGFβ1 expression is similar between MSC isolated from SSc patients and healthy controls, but VEGF or SDF-1 stimulation increases TGFβ1 secretion by SSc MSC only, not healthy controls. In addition, TGFβRI expression is significantly lower in SSc MSC compared to healthy controls [239]. Stimulation with VEGF, TGFβ, and SDF-1 only increase TGFβRII expression in MSC from SSc patients, not healthy controls. Using *in vitro* assays of capillary morphogenesis on dermal microvascular endothelial cells (MVECs) [239], MSC-conditioned medium from SSc patients was shown to significantly increase capillary morphogenesis compared to MSC-conditioned medium from healthy controls, with pro-angiogenic effects mediated by VEGF and SDF-1.

#### **4.2 Autologous MSC in SSc patients**

In a 24 year-old SSc patient refractory to all conventional first-line treatments, with extensive critical limb ischemia and gangrene, autologous MSC ( $1 \times 10^6$ /Kg) was infused at Day 0, 30, and 60. Post-infusion angiography showed new vessel formation [240]. In another SSc patient, intramuscular injection of autologous bone marrow-derived mononuclear cells into ischemic limbs reduced the size and number of digital ulcers [241]. Some autologous BM–MSC transplants have had positive outcomes, but results are conflicting.

#### **4.3 Allogeneic MSC in SSc patients**

The feasibility of allogeneic BM-MSC is supported by several small studies in severe SSc patients, with follow-up varying between 6 and 44 months. Improvement in skin ulcers and reduction in skin fibrosis has been reported in 6 patients to date [242,243]. One clinical case reported an allogeneic BM-MSC transplant from a father to his 41-year old daughter with diffuse cutaneous SSc [242]. Vascular ultrasound 6 months after transplantation revealed a marked improvement in perfusion of hands and fingers, and revascularization of the patient's extremities was confirmed on angiography. A follow-up study by the same group investigated MSC in 5 patients with severe SSc, with follow-ups ranging from 6 to 44 months, without any major adverse events [243]. Two of the patients received fresh MSC, and 3 were injected with MSC isolated from cryopreserved tissue. One patient died of cardiac arrest related to disease progression 18 months after treatment.

One Chinese study investigated the combination of plasmapheresis (PE) and allogeneic MSC in systemic sclerosis [244]. Fourteen patients received three repeated PE treatments with subsequent pulse

cyclophosphamide on days 1, 2, and 5. UC-MSc infusion on day 8. At 12-month follow-up, patients exhibited improvements in the modified Rodnan skin score ( $20.1 \pm 3.1$  versus  $13.8 \pm 10.2$ ;  $P < 0.001$ ). A subset of patients with interstitial lung disease experienced an improvement in lung function and on computed tomography (CT) scans. Scl70 antibodies, serum TGF- $\beta$ , and EGF levels were also significantly decreased at 12-month follow-up.

A phase I/II dose escalation trial of a single IV infusion of allogenic BM-MSc in diffuse SSc refractory to standard therapy is ongoing in France (ClinicalTrials.gov Identifier: NCT02213705), with 20/20 patients included as of September, 2020. There are 4 additional trials of MSc for SSc patients in November 2020 registered at clinicaltrials.gov, of which 2 involve BM-MSc (in Netherlands, NCT03211793, using intramuscular injections for severe ischemia and the other in China through IV infusion, NCT00962923, started in 2009 with unknown status), 1 involves autologous AD-MSc (in France, NCT04356755) through digital infusion, and 1 involves UC-MSc (in Canada, (NCT04356287)) through IV infusion.

## CONCLUSION

*In vitro* studies have demonstrated that MSc have the potential to target the three pathological disease components in SSc progression. Pre-clinical studies in animal models of SSc confirmed that MSc transplant can reduce inflammation, as well as skin and lung fibrosis. The characterization of the MSc secretome and standardization of functional markers of potency, release potency assays, and tests for assessing MSc functional properties have paved the way for conducting clinical trials with reproducible results. Early human trials in SSc patients are showing that MSc transplant can result in regression of skin fibrosis, reductions in skin ulcers and recovery of circulation in the extremities, as well as improvements in lung function. To increase the success of MSc based clinical trials in SSc, the design and validation of relevant preclinical models and potency assays with good predictive value are required, with adequate clinical study design, based on immune profiling strategies allowing patient screening and follow-up. Ongoing studies will help establish the appropriate choice of MSc source in different clinical settings, optimal MSc characteristics and priming, as well as the method of delivery.

## Fundings:

This work was supported in part by the “Agence de Biomedecine”, the “Association Cordon de Vie” and “the Fonds de Dotation de l’AFER pour la Recherche Médicale”.

## REFERENCES

- [1] Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. *N Engl J Med* 2009;360:1989–2003. <https://doi.org/10.1056/NEJMra0806188>.
- [2] Fuschiotti P. Current perspectives on the immunopathogenesis of systemic sclerosis. *Immunotargets Ther* 2016;5:21–35. <https://doi.org/10.2147/ITT.S82037>.
- [3] Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, et al. Impact of pain in health related quality of life of patients with systemic sclerosis. *Rheumatology (Oxford)* 2006;45:1298–302. <https://doi.org/10.1093/rheumatology/kel189>.
- [4] Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, et al. Health-related quality of life in systemic sclerosis: a systematic review. *Arthritis Rheum* 2009;61:1112–20. <https://doi.org/10.1002/art.24676>.
- [5] Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. *Semin Arthritis Rheum* 2014;44:208–19. <https://doi.org/10.1016/j.semarthrit.2014.05.010>.
- [6] Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. *Ann Rheum Dis* 2017;76:1897–905. <https://doi.org/10.1136/annrheumdis-2017-211448>.
- [7] Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017;390:1685–99. [https://doi.org/10.1016/S0140-6736\(17\)30933-9](https://doi.org/10.1016/S0140-6736(17)30933-9).
- [8] Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. *Nat Rev Rheumatol* 2018;14:511–27. <https://doi.org/10.1038/s41584-018-0062-0>.
- [9] Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. *Arthritis & Rheumatology (Hoboken, NJ)* 2017;69:1067–77. <https://doi.org/10.1002/art.40027>.
- [10] Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. *Ann Rheum Dis* 2011;70:1788–92.
- [11] Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017;76:1327–39. <https://doi.org/10.1136/annrheumdis-2016-209909>.
- [12] Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). *Ann Rheum Dis* 2017.
- [13] van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *Jama* 2014;311:2490–8.
- [14] Burt RK, Shah SJ, Dill K, Grant T, Gheorghide M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. *Lancet* 2011;378:498–506.
- [15] Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, et al. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 2018;24:1961–4. <https://doi.org/10.1016/j.bbmt.2018.06.025>.

- [16] Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, et al. Skin involvement in scleroderma--where histological and clinical scores meet. *Rheumatology (Oxford)* 2007;46:833–41.
- [17] Launay D, Marjanovic Z, de Bazelaire C, Florea L, Zohar S, Keshtmand H, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. *J Rheumatol* 2009;36:1460–3.
- [18] Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. *Bone Marrow Transplant* 2017;52:1495–503. <https://doi.org/10.1038/bmt.2017.56>.
- [19] Burt RK, Farge D. Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? *Nat Rev Rheumatol* 2018;14:189–91. <https://doi.org/10.1038/nrrheum.2018.34>.
- [20] Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 1976;4:267–74.
- [21] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–7. <https://doi.org/10.1080/14653240600855905>.
- [22] Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. *Cytotherapy* 2013;15:1054–61.
- [23] Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. *Cytotherapy* 2016;18:151–9. <https://doi.org/10.1016/j.jcyt.2015.11.008>.
- [24] Caplan AI. Mesenchymal stem cells: time to change the name! *Stem Cells Translational Medicine* 2017;6:1445–51.
- [25] Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. *Immunol Lett* 2015;168:140–6. <https://doi.org/10.1016/j.imlet.2015.05.004>.
- [26] de Castro LL, Lopes-Pacheco M, Weiss DJ, Cruz FF, Rocco PRM. Current understanding of the immunosuppressive properties of mesenchymal stromal cells. *J Mol Med (Berl)* 2019;97:605–18. <https://doi.org/10.1007/s00109-019-01776-y>.
- [27] Rozier P, Maria A, Goulabchand R, Jorgensen C, Guilpain P, Noël D. Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? *Front Immunol* 2018;9:2938. <https://doi.org/10.3389/fimmu.2018.02938>.
- [28] Cras A, Farge D, Carmoi T, Lataillade JJ, Wang DD, Sun L. Update on mesenchymal stem cell-based therapy in lupus and scleroderma. *Arthritis Res Ther* 2015;17:301.
- [29] Angiolilli C, Marut W, van der Kroef M, Chouri E, Reedquist KA, Radstake T. New insights into the genetics and epigenetics of systemic sclerosis. *Nat Rev Rheumatol* 2018;14:657–73. <https://doi.org/10.1038/s41584-018-0099-0>.
- [30] Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. *Arthritis Rheum* 2003;48:1956–63. <https://doi.org/10.1002/art.11173>.
- [31] Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three

- United States cohorts. *Arthritis Rheum* 2001;44:1359–62. [https://doi.org/10.1002/1529-0131\(200106\)44:6<1359::AID-ART228>3.0.CO;2-S](https://doi.org/10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S).
- [32] Lopez-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, et al. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. *Nat Commun* 2019;10:4955. <https://doi.org/10.1038/s41467-019-12760-y>.
- [33] Walczyk M, Paradowska-Gorycka A, Olesinska M. Epigenetics: The Future Direction in Systemic Sclerosis. *Scand J Immunol* 2017;86:427–35. <https://doi.org/10.1111/sji.12595>.
- [34] Martin JE, Bossini-Castillo L, Martin J. Unraveling the genetic component of systemic sclerosis. *Hum Genet* 2012;131:1023–37. <https://doi.org/10.1007/s00439-011-1137-z>.
- [35] Tsou P-S, Sawalha AH. Unfolding the pathogenesis of scleroderma through genomics and epigenomics. *J Autoimmun* 2017;83:73–94. <https://doi.org/10.1016/j.jaut.2017.05.004>.
- [36] Broen JCA, Radstake TRDJ, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. *Nature Reviews Rheumatology* 2014;10:671–81. <https://doi.org/10.1038/nrrheum.2014.128>.
- [37] Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. *Nat Rev Rheumatol* 2010;6:453–60. <https://doi.org/10.1038/nrrheum.2010.102>.
- [38] Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. *Autoimmunity Reviews* 2017;16:774–86.
- [39] Fleischmajer R, Perlish JS. Capillary alterations in scleroderma. *J Am Acad Dermatol* 1980;2:161–70. [https://doi.org/10.1016/s0190-9622\(80\)80396-3](https://doi.org/10.1016/s0190-9622(80)80396-3).
- [40] Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. *Arthritis Rheum* 1984;27:645–53.
- [41] Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. *Autoimmun Rev* 2010;10:65–73.
- [42] Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. *N Engl J Med* 2006;354:2667–76.
- [43] Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. *Arthritis & Rheumatology* 2018;70:912–9. <https://doi.org/10.1002/art.40455>.
- [44] Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. *J Rheumatol* 1992;19:1202–6.
- [45] Kråling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. *Pathobiology* 1995;63:48–56. <https://doi.org/10.1159/000163933>.
- [46] Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. *Arthritis Res Ther* 2010;12:R128. <https://doi.org/10.1186/ar3066>.

- [47] Carvalheiro T, Zimmermann M, Radstake T, Marut W. Novel insights into dendritic cells in the pathogenesis of systemic sclerosis. *Clin Exp Immunol* 2020. <https://doi.org/10.1111/cei.13417>.
- [48] Christmann RB, Sampaio-Barros P, Stifano G, Borges CL, de Carvalho CR, Kairalla R, et al. Association of Interferon- and transforming growth factor  $\beta$ -regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. *Arthritis Rheumatol* 2014;66:714–25. <https://doi.org/10.1002/art.38288>.
- [49] Chizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. *Seminars in Immunopathology* 2015;37:519–28. <https://doi.org/10.1007/s00281-015-0509-1>.
- [50] Fuschiotti P. T cells and cytokines in systemic sclerosis. *Curr Opin Rheumatol* 2018;30:594–9. <https://doi.org/10.1097/BOR.0000000000000553>.
- [51] Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. *Curr Opin Rheumatol* 2008;20:707–12.
- [52] Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. *Autoimmun Rev* 2016;15:155–61.
- [53] Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. *PLoS One* 2019;14:e0214202. <https://doi.org/10.1371/journal.pone.0214202>.
- [54] Laurent P, Sisirak V, Lazaro E, Richez C, Duffau P, Blanco P, et al. Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances. *Front Immunol* 2018;9:1702. <https://doi.org/10.3389/fimmu.2018.01702>.
- [55] Assassi S, Wang X, Chen G, Goldmuntz E, Keyes-Elstein L, Ying J, et al. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. *Ann Rheum Dis* 2019;78:1371–8. <https://doi.org/10.1136/annrheumdis-2019-215770>.
- [56] Assassi S, Swindell WR, Wu M, Tan FD, Khanna D, Furst DE, et al. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. *Arthritis Rheumatol* 2015;67:3016–26.
- [57] Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. *PLoS Computational Biology* 2015;11:e1004005. <https://doi.org/10.1371/journal.pcbi.1004005>.
- [58] Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. *Ann Rheum Dis* 2019. <https://doi.org/10.1136/annrheumdis-2019-215894>.
- [59] Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, et al. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. *JCI Insight* 2016;1. <https://doi.org/10.1172/jci.insight.89073>.
- [60] Bhattacharyya S, Varga J. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis. *Curr Rheumatol Rep* 2015;17:474. <https://doi.org/10.1007/s11926-014-0474-z>.
- [61] Brown M, O'Reilly S. Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: advances and opportunities for therapy. *Curr Opin Rheumatol* 2018;30:600–5. <https://doi.org/10.1097/BOR.0000000000000542>.

- [62] Korman B. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis. *Transl Res* 2019. <https://doi.org/10.1016/j.trsl.2019.02.010>.
- [63] Lu TT. Dendritic cells: novel players in fibrosis and scleroderma. *Curr Rheumatol Rep* 2012;14:30–8. <https://doi.org/10.1007/s11926-011-0215-5>.
- [64] Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor- $\beta$  Responses. *Am J Pathol* 2013;182:192–205. <https://doi.org/10.1016/j.ajpath.2012.09.007>.
- [65] Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. *Ann Rheum Dis* 2010;69:1396–402. <https://doi.org/10.1136/ard.2009.121400>.
- [66] Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. *J Immunol* 2002;168:3649–59.
- [67] Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. *Ann Rheum Dis* 2005;64:1233–5. <https://doi.org/10.1136/ard.2004.027094>.
- [68] Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA Jr. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. *Arthritis Rheum* 2013;65:236–46. <https://doi.org/10.1002/art.37706>.
- [69] Luzina IG, Atamas SP, Wise R, Wigley FM, Choi J, Xiao HQ, et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. *Arthritis Rheum* 2003;48:2262–74. <https://doi.org/10.1002/art.11080>.
- [70] Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. *Semin Arthritis Rheum* 2010;40:73–88. <https://doi.org/10.1016/j.semarthrit.2008.10.009>.
- [71] Zhang M, Zhang S. T Cells in Fibrosis and Fibrotic Diseases. *Front Immunol* 2020;11. <https://doi.org/10.3389/fimmu.2020.01142>.
- [72] Ricard L, Jachiet V, Malard F, Ye Y, Stocker N, Rivière S, et al. Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. *Ann Rheum Dis* 2019;78:539–50. <https://doi.org/10.1136/annrheumdis-2018-214382>.
- [73] Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K, et al. T follicular helper-like cells contribute to skin fibrosis. *Sci Transl Med* 2018;10:eaaf5307. <https://doi.org/10.1126/scitranslmed.aaf5307>.
- [74] Baraut J, Farge D, Ivan-Grigore E, Verrecchia F, Michel L. Cytokines in Systemic Sclerosis: Focus on IL-17. *Systemic Sclerosis - An Update on the Aberrant Immune System and Clinical Features* 2012. <https://doi.org/10.5772/28595>.
- [75] Dufour AM, Borowczyk-Michalowska J, Alvarez M, Truchetet ME, Modarressi A, Brembilla NC, et al. IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis. *J Invest Dermatol* 2020;140:103-112 e8. <https://doi.org/10.1016/j.jid.2019.05.026>.
- [76] Chizzolini C, Dufour AM, Brembilla NC. Is there a role for IL-17 in the pathogenesis of systemic sclerosis? *Immunol Lett* 2018;195:61–7. <https://doi.org/10.1016/j.imlet.2017.09.007>.

- [77] Chia JJ, Lu TT. Update on macrophages and innate immunity in scleroderma. *Curr Opin Rheumatol* 2015;27:530–6. <https://doi.org/10.1097/BOR.0000000000000218>.
- [78] MacDonald KG, Dawson NA, Huang Q, Dunne JV, Levings MK, Broady R. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. *J Allergy Clin Immunol* 2015;135:946–e9. <https://doi.org/10.1016/j.jaci.2014.12.1932>.
- [79] Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M, et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. *Ann Rheum Dis* 2012;71:1227–34. <https://doi.org/10.1136/annrheumdis-2011-200709>.
- [80] Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic sclerosis. *Ann Rheum Dis* 2011;70:1475–81. <https://doi.org/10.1136/ard.2009.116525>.
- [81] Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. *PLoS One* 2009;4:e5981.
- [82] Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. *Br J Dermatol* 2010;162:1056–63. <https://doi.org/10.1111/j.1365-2133.2010.09633.x>.
- [83] Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A, et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. *Cell Immunol* 2010;261:77–80. <https://doi.org/10.1016/j.cellimm.2009.12.009>.
- [84] Baraut J, Grigore EI, Jean-Louis F, Khelifa SH, Durand C, Verrecchia F, et al. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. *Bone Marrow Transplant* 2014;49:349–54.
- [85] Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear Antibodies in Systemic Sclerosis: an Update. *Clin Rev Allergy Immunol* 2020;58:40–51. <https://doi.org/10.1007/s12016-018-8718-8>.
- [86] Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. *Arthritis and Rheumatism* 2004;50:1918–27. <https://doi.org/10.1002/art.20274>.
- [87] Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100:12319–24. <https://doi.org/10.1073/pnas.1635114100>.
- [88] Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. *Arthritis Rheum* 2007;56:3167–8. <https://doi.org/10.1002/art.22847>.
- [89] Matsushita T, Hasegawa M, Yanaba K, Koder M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. *Arthritis Rheum* 2006;54:192–201. <https://doi.org/10.1002/art.21526>.
- [90] Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, et al. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis. *Arthritis Rheumatol* 2016;68:494–504.



- [91] Verrecchia F, Mauviel A, Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. *Autoimmun Rev* 2006;5:563–9.
- [92] Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. *Trends Immunol* 2005;26:587–95.
- [93] Lafyatis R. Transforming growth factor  $\beta$ -at the centre of systemic sclerosis. *Nat Rev Rheumatol* 2014;10:706–19. <https://doi.org/10.1038/nrrheum.2014.137>.
- [94] Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. *Autoimmun Rev* 2011;10:267–75. <https://doi.org/10.1016/j.autrev.2010.09.015>.
- [95] Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. *Cytotherapy* 2019;21:1019–24. <https://doi.org/10.1016/j.jcyt.2019.08.002>.
- [96] Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. *Stem Cell Res Ther* 2016;7:125. <https://doi.org/10.1186/s13287-016-0363-7>.
- [97] Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells* 2006;24:386–98.
- [98] Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2008;2:141–50.
- [99] Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. *Eur J Immunol* 2008;38:1745–55. <https://doi.org/10.1002/eji.200738129>.
- [100] Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. *NPJ Regen Med* 2019;4:22. <https://doi.org/10.1038/s41536-019-0083-6>.
- [101] Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. *Cell Mol Life Sci* 2019;76:3323–48. <https://doi.org/10.1007/s00018-019-03125-1>.
- [102] Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. *Nature Reviews Nephrology* 2018;14:493–507. <https://doi.org/10.1038/s41581-018-0023-5>.
- [103] Menard C, Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. *Stem Cell Research & Therapy* 2013;4:64. <https://doi.org/10.1186/scrt214>.
- [104] Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. *Hum Gene Ther* 2011;22:19–26. <https://doi.org/10.1089/hum.2010.197>.
- [105] Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003;31:890–6.
- [106] Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol* 2003;57:11–20.

- [107] Menard C, Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. *Stem Cell Res Ther* 2013;4:64. <https://doi.org/10.1186/scrt214>.
- [108] Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. *Cell Stem Cell* 2014;14:141–5. <https://doi.org/10.1016/j.stem.2014.01.013>.
- [109] Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. *Nature Biotechnology* 2014;32:252.
- [110] Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. *J Cell Biochem* 2006;98:1076–84. <https://doi.org/10.1002/jcb.20886>.
- [111] Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 2006;24:1294–301. <https://doi.org/10.1634/stemcells.2005-0342>.
- [112] Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). *Cytotherapy* 2013;15:641–8. <https://doi.org/10.1016/j.jcyt.2013.02.006>.
- [113] Sacchetti B, Funari A, Remoli C, Giannicola G, Kogler G, Liedtke S, et al. No identical “mesenchymal stem cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. *Stem Cell Reports* 2016;6:897–913.
- [114] Montesinos JJ, Flores-Figueroa E, Castillo-Medina S, Flores-Guzman P, Hernandez-Estevez E, Fajardo-Orduna G, et al. Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. *Cytotherapy* 2009;11:163–76. <https://doi.org/10.1080/14653240802582075>.
- [115] Sivasubramaniyan K, Lehnen D, Ghazanfari R, Sobiesiak M, Harichandan A, Mortha E, et al. Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. *Ann N Y Acad Sci* 2012;1266:94–106. <https://doi.org/10.1111/j.1749-6632.2012.06551.x>.
- [116] Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. *Stem Cell Res Ther* 2013;4:125. <https://doi.org/10.1186/scrt336>.
- [117] Avanzini MA, Bernardo ME, Cometa AM, Perotti C, Zaffaroni N, Novara F, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. *Haematologica* 2009;94:1649–60. <https://doi.org/10.3324/haematol.2009.006171>.
- [118] Kizilay Mancini O, Lora M, Cuillerier A, Shum-Tim D, Hamdy R, Burelle Y, et al. Mitochondrial Oxidative Stress Reduces the Immunopotency of Mesenchymal Stromal Cells in Adults With Coronary Artery Disease. *Circ Res* 2018;122:255–66. <https://doi.org/10.1161/CIRCRESAHA.117.311400>.
- [119] Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. *British Journal of Haematology* 2005;129:118–29.

- [120] Menard C, Dulong J, Roulois D, Hebraud B, Verdiere L, Pangault C, et al. Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. *Stem Cells* 2020;38:146–59. <https://doi.org/10.1002/stem.3077>.
- [121] Araujo AB, Salton GD, Furlan JM, Schneider N, Angeli MH, Laureano AM, et al. Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord. *Cytotherapy* 2017;19:577–85. <https://doi.org/10.1016/j.jcyt.2017.03.001>.
- [122] La Rocca G, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. *Curr Stem Cell Res Ther* 2013;8:100–13. <https://doi.org/10.2174/1574888x11308010012>.
- [123] Abumaree M, Abomaray F, Alshabibi M, AlAskar A, Kalionis B. Immunomodulatory properties of human placental mesenchymal stem/stromal cells. *Placenta* 2017;59:87–95.
- [124] Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. *Stem Cells* 2008;26:2865–74. <https://doi.org/10.1634/stemcells.2007-1028>.
- [125] Barrett AN, Fong C-Y, Subramanian A, Liu W, Feng Y, Choolani M, et al. Human Wharton's Jelly Mesenchymal Stem Cells Show Unique Gene Expression Compared with Bone Marrow Mesenchymal Stem Cells Using Single-Cell RNA-Sequencing. *Stem Cells Dev* 2019;28:196–211. <https://doi.org/10.1089/scd.2018.0132>.
- [126] Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. *Cytometry A* 2018;93:19–31. <https://doi.org/10.1002/cyto.a.23242>.
- [127] Loisel S, Dulong J, Ménard C, Renoud M-L, Meziere N, Isabelle B, et al. Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence. *STEM CELLS* 2017;35:1431–6. <https://doi.org/10.1002/stem.2580>.
- [128] Chinnadurai R, Rajan D, Ng S, McCullough K, Arafat D, Waller EK, et al. Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN $\gamma$  priming. *Blood Adv* 2017;1:628–43. <https://doi.org/10.1182/bloodadvances.2017006205>.
- [129] Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, et al. Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN $\gamma$  Licensing. *Stem Cells* 2016;34:2429–42. <https://doi.org/10.1002/stem.2415>.
- [130] Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? *Stem Cells* 2014;32:2430–42. <https://doi.org/10.1002/stem.1729>.
- [131] Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A. Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. *Cytotherapy* 2015;17:38–45. <https://doi.org/10.1016/j.jcyt.2014.06.008>.
- [132] Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood* 2005;105:4120–6.

- [133] Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. *Transplantation* 2007;83:71–6.
- [134] Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* 2005;105:2214–9.
- [135] Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood* 2005;105:2821–7.
- [136] Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. *J Immunol* 2010;185:6617–23. <https://doi.org/10.4049/jimmunol.1002239>.
- [137] Wang Q, Sun B, Wang D, Ji Y, Kong Q, Wang G, et al. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. *Scand J Immunol* 2008;68:607–15. <https://doi.org/10.1111/j.1365-3083.2008.02180.x>.
- [138] English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. *Clinical and Experimental Immunology* 2009;156:149–60. <https://doi.org/10.1111/j.1365-2249.2009.03874.x>.
- [139] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005;105:1815–22.
- [140] Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. *Exp Hematol* 2008;36:309–18. <https://doi.org/10.1016/j.exphem.2007.11.007>.
- [141] Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. *Stem Cell Res Ther* 2011;2:34. <https://doi.org/10.1186/scrt75>.
- [142] Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. *Haematologica* 2007;92:881–8.
- [143] Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood* 2008;111:1327–33. <https://doi.org/10.1182/blood-2007-02-074997>.
- [144] Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borrás FE, Betjes MGH, et al. Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. *Front Immunol* 2017;8:1042. <https://doi.org/10.3389/fimmu.2017.01042>.
- [145] Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. *Stem Cells and Development* 2015;24:93–103. <https://doi.org/10.1089/scd.2014.0155>.
- [146] Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, et al. Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression. *The Journal of Immunology* 2010;184:2321–8. <https://doi.org/10.4049/jimmunol.0902023>.
- [147] Espagnol N, Balguerie A, Arnaud E, Sensebé L, Varin A. CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of

- Human Mesenchymal Stromal Cells. *Stem Cell Reports* 2017;8:961–76. <https://doi.org/10.1016/j.stemcr.2017.02.008>.
- [148] Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. *Cell Stem Cell* 2012;10:544–55. <https://doi.org/10.1016/j.stem.2012.03.007>.
- [149] Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *Eur J Immunol* 2005;35:1482–90.
- [150] Luz-Crawford P, Noël D, Fernandez X, Khoury M, Figueroa F, Carrión F, et al. Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway. *PLOS ONE* 2012;7:e45272. <https://doi.org/10.1371/journal.pone.0045272>.
- [151] Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. *Transplantation* 2003;76:1208–13.
- [152] Poggi A, Prevosto C, Massaro A-M, Negrini S, Urbani S, Pierri I, et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of Nkp30 and NKG2D receptors. *J Immunol* 2005;175:6352–60. <https://doi.org/10.4049/jimmunol.175.10.6352>.
- [153] Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 2006;107:1484–90.
- [154] Götherström C, Lundqvist A, Duprez IR, Childs R, Berg L, le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. *Cytotherapy* 2011;13:269–78. <https://doi.org/10.3109/14653249.2010.523077>.
- [155] DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. *Tissue Eng Part A* 2009;15:2795–806. <https://doi.org/10.1089/ten.TEA.2008.0630>.
- [156] Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. *Cytotherapy* 2012;14:147–52. <https://doi.org/10.3109/14653249.2011.623691>.
- [157] Qin Y, Zhou Z, Zhang F, Wang Y, Shen B, Liu Y, et al. Induction of Regulatory B-Cells by Mesenchymal Stem Cells is Affected by SDF-1 $\alpha$ -CXCR7. *CPB* 2015;37:117–30. <https://doi.org/10.1159/000430338>.
- [158] Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. *Blood* 2010;116:3770–9. <https://doi.org/10.1182/blood-2010-02-270777>.
- [159] Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Sioud, M, Mobergslien, A, Boudabous, A and Fløisand, Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. *Int J Oncol* 38: 385-390. *International Journal of Oncology* 2011;38:385–90. <https://doi.org/10.3892/ijo.2010.869>.
- [160] Yang S-H, Park M-J, Yoon I-H, Kim S-Y, Hong S-H, Shin J-Y, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. *Exp Mol Med* 2009;41:315–24. <https://doi.org/10.3858/emmm.2009.41.5.035>.

- [161] Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. *J Immunol* 2010;184:5885–94. <https://doi.org/10.4049/jimmunol.0903143>.
- [162] Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> regulatory T cells. *Stem Cells* 2008;26:212–22.
- [163] Terraza-Aguirre C, Campos-Mora M, Elizondo-Vega R, Contreras-López RA, Luz-Crawford P, Jorgensen C, et al. Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells. *Cells* 2020;9:1660. <https://doi.org/10.3390/cells9071660>.
- [164] Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009;15:42–9. <https://doi.org/10.1038/nm.1905>.
- [165] Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. *PLoS One* 2010;5:e9252. <https://doi.org/10.1371/journal.pone.0009252>.
- [166] Giri J, Das R, Nysten E, Chinnadurai R, Galipeau J. CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10<sup>+</sup> Tissue Macrophages to Mitigate Gut Injury. *Cell Reports* 2020;30:1923-1934.e4. <https://doi.org/10.1016/j.celrep.2020.01.047>.
- [167] Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. *Blood* 2011;118:330–8. <https://doi.org/10.1182/blood-2010-12-327353>.
- [168] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* 2009;5:54–63.
- [169] Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AEI, et al. TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. *J Immunol* 2014;192:2177–85. <https://doi.org/10.4049/jimmunol.1300194>.
- [170] Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34<sup>+</sup>-derived and monocyte-derived dendritic cells. *J Immunol* 2006;177:2080–7.
- [171] Kennelly H, Mahon BP, English K. Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD. *Scientific Reports* 2016;6:38207. <https://doi.org/10.1038/srep38207>.
- [172] Lee HJ, Ko JH, Kim HJ, Jeong HJ, Oh JY. Mesenchymal stromal cells induce distinct myeloid-derived suppressor cells in inflammation. *JCI Insight* 2020;5. <https://doi.org/10.1172/jci.insight.136059>.
- [173] Yen BL, Yen ML, Hsu PJ, Liu KJ, Wang CJ, Bai CH, et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via

- hepatocyte growth factor/c-Met and STAT3. *Stem Cell Reports* 2013;1:139–51.  
<https://doi.org/10.1016/j.stemcr.2013.06.006>.
- [174] Zhang B, Yin Y, Lai RC, Tan SS, Choo ABH, Lim SK. Mesenchymal stem cells secrete immunologically active exosomes. *Stem Cells Dev* 2014;23:1233–44.  
<https://doi.org/10.1089/scd.2013.0479>.
- [175] Zhang B, Yeo RWY, Lai RC, Sim EWK, Chin KC, Lim SK. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway. *Cytotherapy* 2018;20:687–96.  
<https://doi.org/10.1016/j.jcyt.2018.02.372>.
- [176] Favaro E, Carpanetto A, Caorsi C, Giovarelli M, Angelini C, Cavallo-Perin P, et al. Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. *Diabetologia* 2016;59:325–33.  
<https://doi.org/10.1007/s00125-015-3808-0>.
- [177] Hyvärinen K, Holopainen M, Skirdenko V, Ruhanen H, Lehenkari P, Korhonen M, et al. Mesenchymal Stromal Cells and Their Extracellular Vesicles Enhance the Anti-Inflammatory Phenotype of Regulatory Macrophages by Downregulating the Production of Interleukin (IL)-23 and IL-22. *Front Immunol* 2018;9.  
<https://doi.org/10.3389/fimmu.2018.00771>.
- [178] Biswas S, Mandal G, Chowdhury SR, Purohit S, Payne KK, Anadon C, et al. EXOSOMES PRODUCED BY MESENCHYMAL STEM CELLS DRIVE DIFFERENTIATION OF MYELOID CELLS INTO IMMUNOSUPPRESSIVE M2-POLARIZED MACROPHAGES IN BREAST CANCER. *J Immunol* 2019;203:3447–60.  
<https://doi.org/10.4049/jimmunol.1900692>.
- [179] Yang R, Huang H, Cui S, Zhou Y, Zhang T, Zhou Y. IFN- $\gamma$  promoted exosomes from mesenchymal stem cells to attenuate colitis via miR-125a and miR-125b. *Cell Death & Disease* 2020;11:1–12. <https://doi.org/10.1038/s41419-020-02788-0>.
- [180] Gowen A, Shahjin F, Chand S, Odegaard KE, Yelamanchili SV. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Challenges in Clinical Applications. *Front Cell Dev Biol* 2020;8. <https://doi.org/10.3389/fcell.2020.00149>.
- [181] Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, et al. Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS. *Stem Cells* 2016;34:2210–23. <https://doi.org/10.1002/stem.2372>.
- [182] Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. *Nat Commun* 2015;6:8472. <https://doi.org/10.1038/ncomms9472>.
- [183] Court AC, Le-Gatt A, Luz-Crawford P, Parra E, Aliaga-Tobar V, Bátiz LF, et al. Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. *EMBO Rep* 2020;21:e48052.  
<https://doi.org/10.15252/embr.201948052>.
- [184] Cheung TS, Galleu A, Bonin M von, Bornhäuser M, Dazzi F. Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cell activity. *1* 2019;104:e438–41.  
<https://doi.org/10.3324/haematol.2018.214767>.

- [185] Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. *Sci Transl Med* 2017;9. <https://doi.org/10.1126/scitranslmed.aam7828>.
- [186] Ketterl N, Brachtl G, Schuh C, Bieback K, Schallmoser K, Reinisch A, et al. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. *Stem Cell Res Ther* 2015;6:236. <https://doi.org/10.1186/s13287-015-0233-8>.
- [187] Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. *Cytotherapy* 2019;21:289–306. <https://doi.org/10.1016/j.jcyt.2018.10.014>.
- [188] Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, et al. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. *Cell Reports* 2018;22:2504–17.
- [189] Giri J, Galipeau J. Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. *Blood Adv* 2020;4:1987–97. <https://doi.org/10.1182/bloodadvances.2020001711>.
- [190] Salem B, Miner S, Hensel NF, Battiwalla M, Keyvanfar K, Stroncek DF, et al. Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. *Cytotherapy* 2015;17:1675–86. <https://doi.org/10.1016/j.jcyt.2015.08.008>.
- [191] Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, et al. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. *Cell Reports* 2018;22:2504–17. <https://doi.org/10.1016/j.celrep.2018.02.013>.
- [192] Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. *Circulation* 2004;109:656–63. <https://doi.org/10.1161/01.CIR.0000114522.38265.61>.
- [193] Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. *Stem Cells (Dayton, Ohio)* 2004;22:377–84. <https://doi.org/10.1634/stemcells.22-3-377>.
- [194] Du WJ, Chi Y, Yang ZX, Li ZJ, Cui JJ, Song BQ, et al. Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta. *Stem Cell Research & Therapy* 2016;7:163. <https://doi.org/10.1186/s13287-016-0418-9>.
- [195] Hsieh J-Y, Wang H-W, Chang S-J, Liao K-H, Lee I-H, Lin W-S, et al. Mesenchymal Stem Cells from Human Umbilical Cord Express Preferentially Secreted Factors Related to Neuroprotection, Neurogenesis, and Angiogenesis. *PLOS ONE* 2013;8:e72604. <https://doi.org/10.1371/journal.pone.0072604>.
- [196] Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* 2004;94:678–85. <https://doi.org/10.1161/01.RES.0000118601.37875.AC>.
- [197] Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. *PLoS One* 2008;3:e1886. <https://doi.org/10.1371/journal.pone.0001886>.



- [198] Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. *PLoS One* 2012;7:e35685. <https://doi.org/10.1371/journal.pone.0035685>.
- [199] Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. *Stem Cells* 2007;25:2648–59. <https://doi.org/10.1634/stemcells.2007-0226>.
- [200] Claffey KP, Wilkison WO, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. *J Biol Chem* 1992;267:16317–22.
- [201] Sierra-Honigsmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. *Science* 1998;281:1683–6. <https://doi.org/10.1126/science.281.5383.1683>.
- [202] Nakanishi C, Nagaya N, Ohnishi S, Yamahara K, Takabatake S, Konno T, et al. Gene and protein expression analysis of mesenchymal stem cells derived from rat adipose tissue and bone marrow. *Circ J* 2011;75:2260–8. <https://doi.org/10.1253/circj.cj-11-0246>.
- [203] Hsiao ST, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. *Stem Cells Dev* 2012;21:2189–203. <https://doi.org/10.1089/scd.2011.0674>.
- [204] Kachgal S, Putnam AJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. *Angiogenesis* 2011;14:47–59. <https://doi.org/10.1007/s10456-010-9194-9>.
- [205] Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. *Circulation* 2004;109:1543–9. <https://doi.org/10.1161/01.CIR.0000124062.31102.57>.
- [206] Bai K, Huang Y, Jia X, Fan Y, Wang W. Endothelium oriented differentiation of bone marrow mesenchymal stem cells under chemical and mechanical stimulations. *J Biomech* 2010;43:1176–81. <https://doi.org/10.1016/j.jbiomech.2009.11.030>.
- [207] Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res* 2008;102:77–85. <https://doi.org/10.1161/CIRCRESAHA.107.159475>.
- [208] Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, Murphy M, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. *Circ Res* 2009;104:1410–20. <https://doi.org/10.1161/CIRCRESAHA.108.190926>.
- [209] Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO. Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. *Tissue Eng Part A* 2010;16:2953–66. <https://doi.org/10.1089/ten.TEA.2009.0635>.
- [210] Merfeld-Clauss S, Lupov IP, Lu H, Feng D, Compton-Craig P, March KL, et al. Adipose stromal cells differentiate along a smooth muscle lineage pathway upon endothelial cell contact via induction of activin A. *Circ Res* 2014;115:800–9. <https://doi.org/10.1161/CIRCRESAHA.115.304026>.

- [211] Merfeld-Clauss S, Lupov IP, Lu H, March KL, Traktuev DO. Adipose Stromal Cell Contact with Endothelial Cells Results in Loss of Complementary Vasculogenic Activity Mediated by Induction of Activin A. *Stem Cells* 2015;33:3039–51. <https://doi.org/10.1002/stem.2074>.
- [212] Liu SH, Huang JP, Lee RK, Huang MC, Wu YH, Chen CY, et al. Paracrine factors from human placental multipotent mesenchymal stromal cells protect endothelium from oxidative injury via STAT3 and manganese superoxide dismutase activation. *Biol Reprod* 2010;82:905–13. <https://doi.org/10.1095/biolreprod.109.081828>.
- [213] De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, et al. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. *J Cell Physiol* 2011;226:2131–8. <https://doi.org/10.1002/jcp.22548>.
- [214] Hostettler KE, Gazdhar A, Khan P, Savic S, Tamo L, Lardinois D, et al. Multipotent mesenchymal stem cells in lung fibrosis. *PLoS One* 2017;12:e0181946. <https://doi.org/10.1371/journal.pone.0181946>.
- [215] Batteux F, Kaviani N, Servettaz A. New insights on chemically induced animal models of systemic sclerosis. *Curr Opin Rheumatol* 2011;23:511–8. <https://doi.org/10.1097/BOR.0b013e32834b1606>.
- [216] Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100:8407–11. <https://doi.org/10.1073/pnas.1432929100>.
- [217] Lee SH, Jang AS, Kim YE, Cha JY, Kim TH, Jung S, et al. Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. *Respiratory Research* 2010;11:16. <https://doi.org/10.1186/1465-9921-11-16>.
- [218] Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. *Transplant Proc* 2008;40:1700–5.
- [219] Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. *Am J Respir Cell Mol Biol* 2005;33:145–52. <https://doi.org/10.1165/rcmb.2004-0330OC>.
- [220] Rubio GA, Elliot SJ, Wikramanayake TC, Xia X, Pereira-Simon S, Thaller SR, et al. Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing. *J Cell Physiol* 2018;233:5503–12. <https://doi.org/10.1002/jcp.26418>.
- [221] Moodley Y, Atenza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. *Am J Pathol* 2009;175:303–13.
- [222] Chen W, Xia ZK, Zhang MH, Ding GC, Zhang XY, Wang ZX, et al. Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma. *Asian Pacific Journal of Tropical Medicine* 2017;10:52–6. <https://doi.org/10.1016/j.apjtm.2016.10.005>.
- [223] Servettaz A, Goulvestre C, Kaviani N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. *J Immunol* 2009;182:5855–64. <https://doi.org/10.4049/jimmunol.0803705>.
- [224] Maria ATJ, Toupet K, Maumus M, Rozier P, Vozenin MC, Le Quellec A, et al. Fibrosis Development in HOC1-Induced Systemic Sclerosis: A Multistage Process Hampered by


- Mesenchymal Stem Cells. *Front Immunol* 2018;9:2571.  
<https://doi.org/10.3389/fimmu.2018.02571>.
- [225] Maria AT, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, et al. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. *Journal of Autoimmunity* 2016;70:31–9. <https://doi.org/10.1016/j.jaut.2016.03.013>.
- [226] Maria AT, Toupet K, Bony C, Pirot N, Vozenin MC, Petit B, et al. Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis. *Arthritis & Rheumatology (Hoboken, NJ)* 2016;68:1013–25. <https://doi.org/10.1002/art.39477>.
- [227] Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. *Stem Cells* 2007;25:220–7. <https://doi.org/10.1634/stemcells.2006-0243>.
- [228] Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolazadeh L, et al. In vivo tracking of <sup>111</sup>In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. *Nucl Med Biol* 2011;38:961–7. <https://doi.org/10.1016/j.nucmedbio.2011.03.008>.
- [229] Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 2001;169:12–20.
- [230] Li L, Jiang J. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms. *Front Med* 2011;5:33–9. <https://doi.org/10.1007/s11684-011-0114-1>.
- [231] Galipeau J, Sensébé L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. *Cell Stem Cell* 2018;22:824–33. <https://doi.org/10.1016/j.stem.2018.05.004>.
- [232] Larghero J, Farge D, Braccini A, Lecourt S, Scherberich A, Fois E, et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. *Ann Rheum Dis* 2008;67:443–9.
- [233] Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. *Rheumatology (Oxford)* 2007;46:403–8.
- [234] Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. *Arthritis Rheum* 2006;54:2605–15.
- [235] Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. *Arthritis Rheum* 2007;56:1994–2004.
- [236] Vanneaux V, Farge-Bancel D, Lecourt S, Baraut J, Cras A, Jean-Louis F, et al. Expression of transforming growth factor beta receptor II in mesenchymal stem cells from systemic sclerosis patients. *BMJ Open* 2013;3.
- [237] Cipriani P, Di Benedetto P, Liakouli V, Del Papa B, Di Padova M, Di Ianni M, et al. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells

- (Tregs) with a functional phenotype: implications for cellular-based therapy. *Clin Exp Immunol* 2013;173:195–206. <https://doi.org/10.1111/cei.12111>.
- [238] Griffin M, Ryan CM, Pathan O, Abraham D, Denton CP, Butler PE. Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine. *Stem Cell Research & Therapy* 2017;8:23. <https://doi.org/10.1186/s13287-016-0444-7>.
- [239] Guiducci S, Manetti M, Romano E, Mazzanti B, Ceccarelli C, Dal Pozzo S, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. *Ann Rheum Dis* 70:2011–21.
- [240] Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. *Ann Intern Med* 2010;153:650–4.
- [241] Ishigatsubo Y, Ihata A, Kobayashi H, Hama M, Kirino Y, Ueda A, et al. Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells. *Mod Rheumatol* 2010;20:263–72. <https://doi.org/10.1007/s10165-010-0274-x>.
- [242] Christopheit M, Schendel M, Foll J, Muller LP, Keysser G, Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. *Leukemia* 2008;22:1062–4.
- [243] Keysser G, Christopheit M, Fick S, Schendel M, Taute BM, Behre G, et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. *Arthritis Rheum* 2011;63:2540–2.
- [244] Zhang H, Liang J, Tang X, Wang D, Feng X, Wang F, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. *Arthritis Res Ther* 2017;19:165. <https://doi.org/10.1186/s13075-017-1373-2>.

Table 1 Animal models of Systemic Sclerosis

	Inflammation	Vascular	Autoimmunity	Fibrosis
<b>Spontaneous mutations</b>				
Type 1 tight skin mouse (Tsk1) <i>fibrillin 1 gene</i>	--	<ul style="list-style-type: none"> <li>No vasculopathy</li> <li>Endothelial dysfunction</li> </ul>	✓	Skin
UCD-200/206 chickens <i>Homozygous at the major histocompatibility complex [B-locus]</i>	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration</li> </ul>	<ul style="list-style-type: none"> <li>Microvascular endothelial cell apoptosis</li> </ul>	✓	Esophagus Lung Kidney
<b>Transgenic models</b>				
Type 2 tight skin mouse (Tsk2) <i>(Type III collagen)</i>	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration</li> </ul>	<ul style="list-style-type: none"> <li>No vasculopathy</li> </ul>	✓	Skin
Conditional TGFβRI <sup>ca</sup> Col1a2 <sup>cre-ER</sup> <i>Conditional overexpression of Type I TGF-β receptor (TGFβRI) by fibroblasts at postnatal day 14</i>	<ul style="list-style-type: none"> <li>Systemic inflammation</li> </ul>	<ul style="list-style-type: none"> <li>Thickening of smaller arteries in lung, kidney,</li> </ul>	--	Skin Lung Kidney
Dominant negative TGFβRIIΔk <i>Overexpression of a dominant-negative kinase-deficient type II TGF-β receptor in fibroblasts</i>	<ul style="list-style-type: none"> <li>Minimal</li> </ul>	<ul style="list-style-type: none"> <li>Microvascular alterations in lung</li> </ul>	--	Skin Lung gut
KLF5 <sup>-/+</sup> /Fli1 <sup>-/+</sup> <i>Kruppel-like factor 5 / Friend leukemia integration 1</i>	<ul style="list-style-type: none"> <li>B cell activation</li> </ul>	<ul style="list-style-type: none"> <li>Vasculopathy</li> </ul>	✓	Kidney Heart
uPAR/CD87 <sup>-/+</sup> <i>Urokinase-type plasminogen activator receptor</i>	--	<ul style="list-style-type: none"> <li>Microvascular alterations</li> <li>Impaired angiogenesis</li> </ul>	--	Skin Lung
Fra-2 <i>Fos-related antigen 2</i>	<ul style="list-style-type: none"> <li>Systemic inflammation</li> </ul>	<ul style="list-style-type: none"> <li>Small blood vessel loss in skin and lung</li> <li>Endothelial cell apoptosis</li> </ul>	--	Skin Lung
<b>Chemically-induced models</b>				
Bleomycin	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration</li> </ul>	<ul style="list-style-type: none"> <li>Endothelial cell apoptosis</li> </ul>	✓	Skin Lung
Vinyl chloride	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration</li> </ul>	--	✓	Skin
Hypochlorite (HOCl)	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration in lung</li> </ul>	<ul style="list-style-type: none"> <li>Endothelial cell damage</li> </ul>	✓	Skin Lung
<b>Mismatched immune cell transplant</b>				
Scl-GVHDv1	<ul style="list-style-type: none"> <li>T cells, monocyte, and mast cell infiltration</li> </ul>	--	✓	Skin Lung Kidney
Scl-GVDH 2	<ul style="list-style-type: none"> <li>Inflammatory cell infiltration</li> </ul>	--	✓	Skin Lung Kidney

Figure 1. Mesenchymal Stromal Cells (MSC) for the treatment of Systemic Sclerosis



Due to a dysregulation of adaptive and innate immune responses, SSc leads to a pro-inflammatory microenvironment with high systemic levels of inflammatory cytokines. These pro-inflammatory stimuli shift MSC toward an immunomodulatory state, activating immunomodulatory pathways, such as the production of metabolic enzymes (e.g.: IDO), cytokines (e.g.: IL-6, IL-10, PGE-2), and upregulation of specific membrane proteins (e.g.: ICAM, PDL-1). Activation of these pathways results in the modulation of immune responses through reduction of inflammation and promotion of tissue repair. MSC Immunosuppressive (blue), pro-angiogenic (red) and antifibrotic (green) properties can target the 3 pathogenic pathways of Systemic Sclerosis

## Mesenchymal stromal cells for Systemic sclerosis treatment

Dominique Farge, Séverine Loisel, Pauline Lansiaux, Karin Tarte

Systemic Sclerosis (SSc) is a rare chronic autoimmune orphan disease.

SSc pathogenesis associates vasculopathy, immune dysregulation and fibrosis.

Mesenchymal Stromal Cells (MSC) properties can target the SSc pathogenic triad.

*In vitro and in vivo* MSC properties vary with donor sources and local inflammation.

MSC appear as a new promising stem cell therapy for SSc patients.